US Stock Insider Trading | Oruka Therapeutics disclosed 4 insider transactions on February 17

2026-02-20 22:03:20

On February 17, 2026, Oruka Therapeutics (ORKA) disclosed four insider trading transactions. Executive Goncalves Joana sold 6,064 shares on that date.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 17, 2026	Executive	Goncalves Joana	February 17, 2026	Buy	3,500	7.80	27,300
February 17, 2026	Executive	Goncalves Joana	February 17, 2026	Sell	936	32.78	30,700
February 17, 2026	Executive	Goncalves Joana	February 17, 2026	Sell	6,064	32.30	195,900
February 17, 2026	Executive	Goncalves Joana	February 17, 2026	Buy	3,500	6.84	23,900
January 16, 2026	Executive	Goncalves Joana	January 15, 2026	Sell	2,619	32.24	84,400
January 16, 2026	Executive	Goncalves Joana	January 15, 2026	Sell	4,381	31.56	138,300
January 16, 2026	Executive	Goncalves Joana	January 15, 2026	Buy	3,500	6.84	23,900
January 16, 2026	Executive	Goncalves Joana	January 15, 2026	Buy	3,500	7.80	27,300
January 2, 2026	Executive	Sandler Laura Lee	January 2, 2026	Buy	5,000	7.80	39,000
January 2, 2026	Executive	Sandler Laura Lee	January 2, 2026	Sell	3,144	29.08	91,400

[Company Information]

Oruka Therapeutics, Inc. completed a business merger with ARCA Colorado based on an agreement and reorganization plan dated September 24, 2008, and amended on October 28, 2008. The wholly owned subsidiary of Nuvelo, Inc. merged with ARCA Colorado, which continued as the surviving company and a wholly owned subsidiary of Nuvelo, Inc. Following the merger, the company renamed itself ARCA Biopharma, Inc. Nuvelo was initially incorporated as HYSEQ. The company is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapies for psoriasis, inflammation, and immunological indications.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes